A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis

16Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Several biologics for atopic dermatitis (AD) have demonstrated good efficacy in clinical trials, but with a substantial proportion of patients being identified as poor responders. This study aims to understand the pathophysiological backgrounds of patient variability in drug response, especially for dupilumab, and to identify promising drug targets in dupilumab poor responders. Methods: We conducted model-based meta-analysis of recent clinical trials of AD biologics and developed a mathematical model that reproduces reported clinical efficacies for nine biological drugs (dupilumab, lebrikizumab, tralokinumab, secukinumab, fezakinumab, nemolizumab, tezepelumab, GBR 830, and recombinant interferon-gamma) by describing system-level AD pathogenesis. Using this model, we simulated the clinical efficacy of hypothetical therapies on virtual patients. Results: Our model reproduced reported time courses of %improved EASI and EASI-75 of the nine drugs. The global sensitivity analysis and model simulation indicated the baseline level of IL-13 could stratify dupilumab good responders. Model simulation on the efficacies of hypothetical therapies revealed that simultaneous inhibition of IL-13 and IL-22 was effective, whereas application of the nine biologic drugs was ineffective, for dupilumab poor responders (EASI-75 at 24 weeks: 21.6% vs. max. 1.9%). Conclusion: Our model identified IL-13 as a potential predictive biomarker to stratify dupilumab good responders, and simultaneous inhibition of IL-13 and IL-22 as a promising drug therapy for dupilumab poor responders. This model will serve as a computational platform for model-informed drug development for precision medicine, as it allows evaluation of the effects of new potential drug targets and the mechanisms behind patient variability in drug response.

References Powered by Scopus

A methodology for performing global uncertainty and sensitivity analysis in systems biology

2083Citations
N/AReaders
Get full text

Log-normal distributions across the sciences: Keys and clues

2031Citations
N/AReaders
Get full text

Two Phase 3 Trials of dupilumab versus placebo in atopic dermatitis

1615Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Recent applications of quantitative systems pharmacology and machine learning models across diseases

35Citations
N/AReaders
Get full text

IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis

22Citations
N/AReaders
Get full text

IL-22 as a target for therapeutic intervention: Current knowledge on its role in various diseases

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Miyano, T., Irvine, A. D., & Tanaka, R. J. (2022). A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 77(2), 582–594. https://doi.org/10.1111/all.14870

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 30

65%

Researcher 10

22%

Professor / Associate Prof. 4

9%

Lecturer / Post doc 2

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

39%

Mathematics 13

34%

Pharmacology, Toxicology and Pharmaceut... 6

16%

Biochemistry, Genetics and Molecular Bi... 4

11%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free